Multidrug efflux pumps and cancer stem cells: Insights into multidrug resistance and therapeutic development

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 4, 2011, Pages 491-502

  Moitra, K ^a   Lou, H ^b   Dean, M ^a  

^a Cancer and Inflammation Program   (United States)

^b Basic Science Program SaiC Frederick   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BIRICODAR; BREAST CANCER RESISTANCE PROTEIN; CELL SURFACE MARKER; CURCUMIN; CYCLOSPORIN; FUMETRIMORGIN C; KOL 143; MICRORNA; MULTIDRUG RESISTANCE PROTEIN 1; MYCOTOXIN; NSC 73306; POLYPHENOL; PROTEIN ABCB5; TARIQUIDAR; TETRACYCLINE DERIVATIVE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; ZOSUQUIDAR;

ARTICLE; CANCER STEM CELL; CELL POPULATION; CELL PROTECTION; GENE EXPRESSION REGULATION; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; STEM CELL; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 79952993517     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.14     Document Type: Article

References (50)

1. Novik, A.A., Ionova1, T.I., Gorodokin, G., Smoljaninov, A., Afanasyev, B.V. The Maximow 1909 centenary: a reappraisal. Cell. Ther. Transplant. 1, E.000034.01 (2009).
2. Lobo, N.A., Shimono, Y., Qian, D. & Clarke, M.F. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 23, 675-699 (2007).
3. Morrison, S.J. et al. A genetic determinant that specifically regulates the frequency of hematopoietic stem cells. J. Immunol. 168, 635-642 (2002). (Pubitemid 34049563)
4. Shackleton, M. Normal stem cells and cancer stem cells: similar and different. Semin. Cancer Biol. 20, 85-92 (2010).
5. Dean, M. The Human aTp-Binding Cassette (aBC) Transporter Superfamily. National Center for Biotechnology information http://www.Ncbi.Nlm.Nih. Gov/books/NBK3 (2002).
6. Scharenberg, C.W., Harkey, M.A. & Torok-Storb, B. The aBCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99, 507-512 (2002). (Pubitemid 34533085)
7. Schinkel, A.H. et al. Disruption of the mouse mdr1a p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502 (1994). (Pubitemid 24153990)
8. Tang, L. et al. Hematopoietic stem cells exhibit a specific aBC transporter gene expression profile clearly distinct from other stem cells. BMC Pharmacol. 10, 12 (2010).
9. Alt, R., Wilhelm, F., Pelz-ackermann, O., Egger, D., Niederwieser, D. & Cross, M. ABCG2 expression is correlated neither to side population nor to hematopoietic progenitor function in human umbilical cord blood. Exp. Hematol. 37, 294-301 (2009).
10. Graham, S.M. et al. Primitive, Quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STi571 in vitro. Blood 99, 319-325 (2002).
11. Hirschmann-Jax, C. et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 101, 14228-14233 (2004). (Pubitemid 39305058)
12. Welte, Y., Adjaye, J., Lehrach, H.R. & Regenbrecht, C.R. Cancer stem cells in solid tumors: elusive or illusive? Cell Commun. Signal. 8, 6 (2010).
13. Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (2005). (Pubitemid 40488633)
14. Gottesman, M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627 (2002). (Pubitemid 34177898)
15. Litman, T., Druley, T.E., Stein, W.D. & Bates, S.E. From MDR to MXR: new understanding of multidrug resistance systems, Their properties and clinical significance. Cell. Mol. Life Sci. 58, 931-959 (2001). (Pubitemid 32652819)
16. Bailey-Dell, K.J., Hassel, B., Doyle, L.A. & Ross, D.D. Promoter characterization and genomic organization of the human breast cancer resistance protein (aTp-binding cassette transporter G2) gene. Biochim. Biophys. Acta 1520, 234-241 (2001). (Pubitemid 32868794)
17. Jensen, L.E. & Whitehead, A.S. The 3' untranslated region of the membranebound iL-1R accessory protein mRNa confers tissue-specific destabilization. J. Immunol. 173, 6248-6258 (2004). (Pubitemid 39487783)
18. Ee, P.L., Kamalakaran, S., Tonetti, D., He, X., Ross, D.D. & Beck, W.T. Identification of a novel estrogen response element in the breast cancer resistance protein (aBCG2) gene. Cancer Res. 64, 1247-1251 (2004). (Pubitemid 38235590)
19. Szatmari, I. et al. Peroxisome proliferator-activated receptor gamma-regulated aBCG2 expression confers cytoprotection to human dendritic cells. J. Biol. Chem. 281, 23812-23823 (2006). (Pubitemid 44274157)
20. Wang, H. et al. Progesterone receptor (pR) isoforms pRa and pRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Mol. Pharmacol. 73, 845-854 (2008). (Pubitemid 351397889)
21. Martin, C.M. et al. Hypoxia-inducible factor-2alpha transactivates abcg2 and promotes cytoprotection in cardiac side population cells. Circ. Res. 102, 1075-1081 (2008). (Pubitemid 351667861)
22. Marques, D.S., Sandrini, J.Z., Boyle, R.T., Marins, L.F. & Trindade, G.S. Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines. Leuk. Res. 34, 757-762 (2010).
23. Nakanishi, T. et al. Novel 5' untranslated region variants of BCRp mRNa are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, Tissue-specific expression, And alternative promoter usage. Cancer Res. 66, 5007-5011 (2006). (Pubitemid 43844920)
24. Liao, R. et al. MicroRNas play a role in the development of human hematopoietic stem cells. J. Cell. Biochem. 104, 805-817 (2008). (Pubitemid 351830831)
25. Pan, Y.Z., Morris, M.E. & Yu, A.M. MicroRNa-328 negatively regulates the expression of breast cancer resistance protein (BCRp/aBCG2) in human cancer cells. Mol. Pharmacol. 75, 1374-1379 (2009).
26. To, K.K., Zhan, Z., Litman, T. & Bates, S.E. Regulation of aBCG2 expression at the 3' untranslated region of its mRNa through modulation of transcript stability and protein translation by a putative microRNa in the S1 colon cancer cell line. Mol. Cell. Biol. 28, 5147-5161 (2008).
27. Ambudkar, S.V., Dey, S., Hrycyna, C.A., Ramachandra, M., Pastan, I. & Gottesman, M.M. Biochemical, Cellular, And pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39, 361-398 (1999). (Pubitemid 29222564)
28. Loo, T.W. & Clarke, D.M. Reconstitution of drug-stimulated aTpase activity following co-expression of each half of human p-glycoprotein as separate polypeptides. J. Biol. Chem. 269, 7750-7755 (1994). (Pubitemid 24217990)
29. Zhou, J. et al. Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J. Gastroenterol. 14, 925-930 (2008). (Pubitemid 351325033)
30. Raaijmakers, M.H., De Grouw, E.P., Van der Reijden, B.A., De Witte, T.J., Jansen, J.H. & Raymakers, R.A. ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia. Clin. Cancer Res. 12, 3452-3458 (2006).
31. Scotto, K.W. & Johnson, R.A. Transcription of the multidrug resistance gene MDR1: a therapeutic target. Mol. Interv. 1, 117-125 (2001).
32. Cornwell, M.M. The human multidrug resistance gene: sequences upstream and downstream of the initiation site influence transcription. Cell Growth Differ. 1, 607-615 (1990).
33. Van Groenigen, M., Valentijn, L.J. & Baas, F. Identification of a functional initiator sequence in the human MDR1 promoter. Biochim. Biophys. Acta 1172, 138-146 (1993). (Pubitemid 23065790)
34. Cornwell, M.M. & Smith, D.E. Sp1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J. Biol. Chem. 268, 19505-19511 (1993). (Pubitemid 23270733)
35. Ogretmen, B. & Safa, A.R. Negative regulation of MDR1 promoter activity in MCF-7, But not in multidrug resistant MCF-7/adr, Cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CaaT region. Biochemistry 38, 2189-2199 (1999).
36. Chin, K.V., Ueda, K., Pastan, I. & Gottesman, M.M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255, 459-462 (1992).
37. Johnson, R.A., Shepard, E.M., & Scotto, K.W. Differential regulation of MDR1 transcription by the p53 family members. Role of the DNa binding domain. J. Biol. Chem. 280, 13213-13219 (2005). (Pubitemid 40517204)
38. Jin, W., Scotto, K.W., Hait, W.N. & Yang, J.M. Involvement of CtBp1 in the transcriptional activation of the MDR1 gene in human multidrug resistant cancer cells. Biochem. Pharmacol. 74, 851-859 (2007). (Pubitemid 47212073)
39. Frank, N.Y. et al. Regulation of progenitor cell fusion by aBCB5 p-glycoprotein, A novel human aTp-binding cassette transporter. J. Biol. Chem. 278, 47156-47165 (2003). (Pubitemid 37452302)
40. Frank, N.Y. et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 65, 4320-4333 (2005). (Pubitemid 40775671)
41. Schatton, T. et al. Identification of cells initiating human melanomas. Nature 451, 345-349 (2008).
42. Fukunaga-Kalabis, M. et al. Tenascin-C promotes melanoma progression by maintaining the aBCB5-positive side population. Oncogene 29, 6115-6124 (2010).
43. DeSano, J.T. & Xu, L. MicroRNa regulation of cancer stem cells and therapeutic implications. AAPS J. 11, 682-692 (2009).
44. Kovalchuk, O. et al. Involvement of microRNa-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 7, 2152-2159 (2008).
45. Zhu, H. et al. Role of MicroRNa miR-27a and miR-451 in the regulation of MDR1/p-glycoprotein expression in human cancer cells. Biochem. Pharmacol. 76, 582-588 (2008).
46. Remsberg, J.R., Lou, H., Tarasov, S.G., Dean, M. & Tarasova, N.I. Structural analogues of smoothened intracellular loops as potent inhibitors of Hedgehog pathway and cancer cell growth. J. Med. Chem. 50, 4534-4538 (2007). (Pubitemid 47378850)
47. Mimeault, M. & Batra, S.K. Recent progress on tissue-resident adult stem cell biology and their therapeutic implications. Stem Cell Rev. 4, 27-49 (2008).
48. Wu, C.P., Calcagno, A.M. & Ambudkar, S.V. Reversal of aBC drug transportermediated multidrug resistance in cancer cells: evaluation of current strategies. Curr. Mol. Pharmacol. 1, 93-105 (2008).
49. Ludwig, J.A. et al. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res. 66, 4808-4815 (2006).
50. Wu, C.P., Shukla, S., Calcagno, A.M., Hall, M.D., Gottesman, M.M. & Ambudkar, S.V. Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked aBCG2 transporter. Mol. Cancer Ther. 6, 3287-3296 (2007).